Abstract 1486
Background
Here is no convincing active treatment for patients with PROC. Anti-apoptotic bcl-2 proteins have been implicated in chemotherapy (CT) resistance. In preclinical studies, we demonstrated promising activity of Navitoclax, an anti-apoptotic inhibitor of Bcl-2 family, in ROC tumors, suggesting a potential action in platinum resistant pts. We conducted a multicentric phase II trial of Navitoclax monotherapy and reported modest efficacy (ESMO 2017, abstract #2269). Here we aimed to describe the relationship between Bcl-2 protein expression and response to Navitoclax; we also reported response to subsequent line of CT.
Methods
Pts (N = 46) with high grade serous PROC received oral Navitoclax (150 mg daily for 7 days followed by 250 mg daily) until disease progression or toxicity. All pts had a biopsy of relapsed disease before navitoclax initiation to assess the expression level of Bcl-2 proteins by histoimmunochemistry (IHC), as low, medium or high. We first evaluated the efficacy of Navitoclax for pts with high BIM level, then with high BIM expression combined with low Mcl-1 and/or phospho-ERK. Response to subsequent CT was also described.
Results
44 pts (with median of 4 prior lines) were assessable for efficacy: PFS was 50 days [6-234] with 1 partial response (PR), 15 stable diseases (SD). IHC data were available for 35 pts. BIM was highly expressed in 9 pts, 4 of them with PR/SD (p = 0.68). Among them, 7 had a low expression of Mcl-1 and/or phospho-ERK, of whom 4 with PR/SD, showing no evidence of relation with clinical response. After Navitoclax, 32 pts were retreated with CT: 4PR and 9SD were noted, including 11 pts with long response (6-13 months). Median delay from previous platinum-based treatment to subsequent CT was 9 months [2-23] for PR/SD pts. Especially, 12 pts received platinum after Navitoclax with high response rate (3PR/4SD, 58%), median delay from previous platinum-CT was 18 months.
Conclusions
BIM expression, alone or combined with Mcl-1 and/or pERK, is not predictive of Navitoclax benefit. High proportion of PROC pts response to platinum rechallenge; the potential implication of Navitoclax needs further explorations. Other Bcl-2 family proteins (activator BH3-only BID and PUMA) expression may be more relevant. This trial is granted by the French Cancer Research Hospital Program in 2011 and the Mariapia Bressan award in GINEGEPS 2014.
Clinical trial identification
Eudract: 2015-000193-35.
Legal entity responsible for the study
Centre François Baclesse.
Funding
Abbvie.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5877 - TCR beta chain convergence defines the tumor infiltrating T cell repertoire of melanoma and non-small cell lung carcinoma.
Presenter: Timothy Looney
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3212 - PI3K inhibition and modulation of immune and tumor microenvironment markers by copanlisib in patients with non-Hodgkin's lymphoma or advanced solid tumors
Presenter: Ahmad Awada
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3574 - Pan-squamous genomic profiling stratified by anatomic tumor site and viral association
Presenter: Meagan Montesion
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4113 - Toward the Standardization of Bioinformatics Methods for the Accurate Assessment of Tumor Mutational Burden (TMB)
Presenter: Han Chang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4468 - Prediction of primary resistance to anti-PD1 therapy (APD1) in 2nd line NSCLC
Presenter: Egbert Smit
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4570 - Immunomodulatory germline variation impacts the development of multiple primary melanoma (MPM).
Presenter: Robert Ferguson
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1169 - Leukocyte telomere length and recurrence risk after EGFR-TKIs therapy in patients with advanced lung adenocarcinoma
Presenter: Ming Yang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1707 - Gene embedding: a novel machine learning approach to identify gene candidates related to immunotherapy responsiveness
Presenter: Chi Tung Choy
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2123 - Common and rare DPYD variants are predictive for 5FU/capecitabine (5FU) toxicity: The MRC COIN and COIN-B trials
Presenter: Ayman Madi
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5671 - The landscape of NTRK fusions in Chinese solid tumor patients
Presenter: Qi Ling
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract